Journal
TRENDS IN IMMUNOLOGY
Volume 36, Issue 4, Pages 198-216Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2015.02.006
Keywords
cancer; inflammation; adaptive immune cells; anticancer therapy; mouse model
Categories
Funding
- Marie Curie Intra-European Fellowship [BMDCMET 275610]
- European Research Council Consolidator award [INFLAMET 615300]
- Dutch Cancer Society [2011-5004]
- Worldwide Cancer Research [AICR 11-0677]
- Netherlands Organization for Scientific Research NWO VIDI [917.96.307]
- European Union [FP7 MCA-ITN 317445 TIMCC]
Ask authors/readers for more resources
Conventional anticancer therapies, such as chemotherapy, radiotherapy, and targeted therapy, are designed to kill cancer cells. However, the efficacy of anticancer therapies is not only determined by their direct effects on cancer cells but also by off-target effects within the host immune system. Cytotoxic treatment regimens elicit several changes in immune-related parameters including the composition, phenotype, and function of immune cells. Here we discuss the impact of innate and adaptive immune cells on the success of anticancer therapy. In this context we examine the opportunities to exploit host immune responses to boost tumor clearing, and highlight the challenges facing the treatment of advanced metastatic disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available